Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

Desaturation during the 6-minute walk test is a significant predictive factor for mortality in patients with idiopathic pulmonary fibrosis.

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...

R&D image Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, ...

Brittany Schlater dominated the 2024 CPU Canadian National Championships and unofficially broke the Raw Deadlift IPF World ...

Ade Omisakin has managed to demolish the U83KG IPF Raw Total World Record at the 2024 IPF Western European Powerlifting ...

Boehringer Ingelheim said that it will submit a new drug application for nerandomilast based on the positive results.

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...